// App-Quantinova.ai

: Super-Enhancer-Driven PIM Kinase Upregulation in Multiple Myeloma Maintains the Plasma Cell-Specific Oncogenic and Microenvironmental Circuits, and Can be Efficiently Targeted By the Pan-PIM Inhibitor MEN1703

Researchers

Presenter

  • Filip Garbicz

Principal Investigators

  • Anna Szumera-Cieckiewicz

  • Joanna Barankiewicz

  • Dorota Komar

  • Michał Pawlak

  • Aleksandra Matrejek

  • Thorsten Stuehmer

  • Aleksander Salomon-Perzynski

  • Agata Malenda

  • Julia Ostrowska

  • Julia Dudkiewicz

  • Krzysztof Brzozka

  • Tomasz Rzymski

  • Daniela Bellarosa

  • Ewa Lech-Maranda

  • Monika Prochorec-Sobieszek

  • Zofia Pilch

  • Dominika Nowis

  • Jakub Golab

  • Helen Tanton

  • Teru Hideshima

  • David M. Dorfman

  • Irena Misiewicz-Krzeminska

  • Tomasz Sewastianik

  • Ruben D. Carrasco

  • Maciej Szydlowski

  • Przemyslaw Juszczynski

Medical Centers

  • Centre for Omic Sciences (COS), Eurecat, Centre Tecnològic de Catalunya, Reus, Spain

  • Department of Methodology, Medical University of Warsaw, Warsaw, Poland

  • Ryvu Therapeutics, Cracow, Poland

  • Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland

  • Hematology Department, Institute of Hematology and Transfusion Medicine, Warsaw, Poland

  • Laboratory of Experimental Medicine, Medical University of Warsaw, Warsaw, Poland

  • Centre of Preclinical Research, Medical University of Warsaw, Warsaw, Poland

  • Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (rome), Italy

  • Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland

  • Harvard Medical School, Boston, MA

  • The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Department of Pathology, Dana-Farber Cancer Institute, Boston, MA

  • Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany

  • Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Boston, MA

  • Department of Pathology, Brigham and Women's Hospital, Boston, MA

Locations

  • Spain

  • Poland

  • Germany

  • United States

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Interferon regulatory factor 4

  • cMYC

  • Fms related tyrosine kinase 3

  • Serine/threonine-protein kinase mTOR

  • Janus kinase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved